Apimeds Interest Expense from 2010 to 2026
| APUS Stock | 1.62 0.16 10.96% |
Interest Expense | First Reported 2010-12-31 | Previous Quarter 135.4 K | Current Value 142.1 K | Quarterly Volatility 48.6 K |
Check Apimeds Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apimeds Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 142.1 K, Selling General Administrative of 749.4 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Apimeds financial statements analysis is a perfect complement when working with Apimeds Pharmaceuticals Valuation or Volatility modules.
Apimeds | Interest Expense | Build AI portfolio with Apimeds Stock |
The evolution of Interest Expense for Apimeds Pharmaceuticals US provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Apimeds Pharmaceuticals compares to historical norms and industry peers.
Latest Apimeds Pharmaceuticals' Interest Expense Growth Pattern
Below is the plot of the Interest Expense of Apimeds Pharmaceuticals US over the last few years. It is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. Apimeds Pharmaceuticals' Interest Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Apimeds Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Interest Expense | 10 Years Trend |
|
Interest Expense |
| Timeline |
Apimeds Interest Expense Regression Statistics
| Arithmetic Mean | 31,960 | |
| Geometric Mean | 13,737 | |
| Coefficient Of Variation | 152.22 | |
| Mean Deviation | 35,938 | |
| Median | 6,740 | |
| Standard Deviation | 48,650 | |
| Sample Variance | 2.4B | |
| Range | 135.4K | |
| R-Value | 0.74 | |
| Mean Square Error | 1.2B | |
| R-Squared | 0.54 | |
| Significance | 0.0007 | |
| Slope | 7,098 | |
| Total Sum of Squares | 37.9B |
Apimeds Interest Expense History
About Apimeds Pharmaceuticals Financial Statements
Apimeds Pharmaceuticals shareholders use historical fundamental indicators, such as Interest Expense, to determine how well the company is positioned to perform in the future. Although Apimeds Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Apimeds Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Apimeds Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Interest Expense | 135.4 K | 142.1 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apimeds Stock Analysis
When running Apimeds Pharmaceuticals' price analysis, check to measure Apimeds Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apimeds Pharmaceuticals is operating at the current time. Most of Apimeds Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apimeds Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apimeds Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apimeds Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.